Dimensional Fund Advisors
XFOR icon

Dimensional Fund Advisors’s X4 Pharmaceuticals XFOR Stock Holding History

Dimensional Fund Advisors’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,843
Closed -$76.9K – 3418
2024
Q1 		$76.9K Hold
1,843
– – ﹤0.01% 3291
2023
Q4 		$46.4K Hold
1,843
– – ﹤0.01% 3353
2023
Q3 		$60.3K Hold
1,843
– – ﹤0.01% 3366
2023
Q2 		$107K Sell
1,843
-134
-7% -$6.89K ﹤0.01% 3311
2023
Q1 		$51.6K Hold
1,977
– – ﹤0.01% 3382
2022
Q4 		$59 Hold
1,977
– – ﹤0.01% 3382
2022
Q3 		$101K Sell
1,977
-70
-3% -$2.42K ﹤0.01% 3329
2022
Q2 		$59K Hold
2,047
– – ﹤0.01% 3382
2022
Q1 		$107K Sell
2,047
-159
-7% -$9.12K ﹤0.01% 3386
2021
Q4 		$152K Sell
2,206
-244
-10% -$30.9K ﹤0.01% 3383
2021
Q3 		$389K Sell
2,450
-1,727
-41% -$284K ﹤0.01% 3233
2021
Q2 		$814K Buy
4,177
+2,600
+165% +$654K ﹤0.01% 3069
2021
Q1 		$407K Buy
+1,577
New +$414K ﹤0.01% 3181

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors's XFOR Position: Q2 2024 in Review

Dimensional Fund Advisors sold out of X4 Pharmaceuticals (XFOR) in Q2 2024, closing a stake of 1,843 shares — an estimated $76.9K sold.

Dimensional Fund Advisors first reported a position in XFOR in Q1 2021 and held it in 13 quarters. The position peaked at $814K in Q2 2021. 98 funds tracked by Wall St. Rank hold XFOR as of Q2 2024.

  • Dimensional Fund Advisors reported no remaining X4 Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Dimensional Fund Advisors sold 1,843 X4 Pharmaceuticals shares in Q2 2024, an estimated $76.9K.
  • Dimensional Fund Advisors first reported a position in X4 Pharmaceuticals in Q1 2021 and held it in 13 quarters.
  • Dimensional Fund Advisors's X4 Pharmaceuticals position peaked at $814K in Q2 2021.
  • 98 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2024.

Based on Dimensional Fund Advisors's 13F filing for Q2 2024, filed 9 Aug 2024.